No profile data available.
Ocugen, Inc. (OCGN) is a healthcare company in the eye treatment pharmaceuticals industry, based in Malvern, United States, with about 116 full-time employees.
It reported revenue of $4.41 million for fiscal year 2025, up 8.8% from fiscal year 2024, and net income of -$67.85 million. Its market capitalization was $324.02 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health.
Ocugen reported $4.41 million in revenue for fiscal year 2025, up 8.8% from $4.06 million in fiscal year 2024.
$324.02 million as of October 9, 2026.
Listed companies of a similar size in the same industry (eye treatment pharmaceuticals) include MeiraGTx Holdings plc (MGTX), Opus Genetics, Inc. (IRD), Surrozen, Inc. (SRZN), EyePoint Pharmaceuticals, Inc. (EYPT).